Daniel Ermann, MD, discusses improvements shown in real-world data for zanubrutinib compared with acalabrutinib in treatment-naive CLL.
Back
Assessing Real-World Outcomes With BTK Inhibitor Monotherapy in Treatment-Naive CLL
Ryan Jacobs, MD, and colleagues presented real-world data comparing outcomes for zanubrutinib vs acalabrutinib in treatment-naive CLL.
Assessing Real-World Outcomes With BTK Inhibitor Monotherapy in Treatment-Naive CLL
Episodes
All
All
Real-world data showed zanubrutinib was associated with longer time to next treatment and improved overall survival vs acalabrutinib in treatment-naive CLL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to Olomorasib in KRAS G12C+ Pancreatic Cancer
2
FDA Grants Orphan Drug Designation to Zocilurtatug Pelitecan for Neuroendocrine Carcinomas
3
Sapablursen Represents Potential Avenue for Improved Hepcidin Production in Polycythemia Vera
4
OS Wins, New Approvals, and Practice-Changing Data: Breaking Down the Biggest NSCLC News From ASCO 2026
5